Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II actinomycin D in relapsed/refractory NPM1-mutated acute myeloid leukemia
2014-000693-18Phase 2Completed
- Sponsor
- University of Perugia, Department of Medicine
- Start
- Mar 2014
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of actinomycin D in acute myeloid leukemia (AML), sponsored by University of Perugia, Department of Medicine. Primary endpoint: Complete response rate. Started Mar 2014; status: completed.
02
Drugs
actinomycin D
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2014-000693-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000693-18.